Patents Assigned to The United States Government as represented by the Secretary of the Department of Health and Human Services
-
Patent number: 10441642Abstract: The present disclosure is directed to an immunogenic composition including: at least one or at least two isolated polypeptides or immunogenic fragments thereof, and optionally a pharmaceutically acceptable carrier, wherein each polypeptide is expressed on a luminal surface of an intestine of a filarial worm, wherein each polypeptide is expressed at a level at least two-fold higher in the intestine in comparison to the level of expression of each polypeptide in a reproductive tract or a body wall of the filarial worm, wherein each isolated polypeptide has at least one transmembrane domain, and wherein each polypeptide is a non-mitochondrial polypeptide. Also provided herein is a method for preventing or treating a filarial disease.Type: GrantFiled: March 17, 2016Date of Patent: October 15, 2019Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States Government, as Represented by the Secretary of the Department of Health and Human ServicesInventors: Edward E. Mitre, Christopher Morris, Sasisekhar Bennuru, Thomas Nutman
-
Patent number: 10434116Abstract: The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.Type: GrantFiled: April 7, 2015Date of Patent: October 8, 2019Assignees: University of Maryland, Baltimore, United States Government as represented by the Secretary, Department of Health and Human ServicesInventors: Matthew Frieman, Peter B. Jarhling, Lisa E. Hensley
-
Publication number: 20170027975Abstract: The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.Type: ApplicationFiled: April 7, 2015Publication date: February 2, 2017Applicants: University of Maryland, Baltimore, United States Government as represented by the Secretary, Department of Health and Human ServicesInventors: Matthew Frieman, Peter B. Jarhling, Lisa E. Hensley
-
Publication number: 20130022598Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: ApplicationFiled: May 29, 2012Publication date: January 24, 2013Applicants: The United States Government as represented by the Secretary, Department of Health and Human Service, Duke UniversityInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles N. Pegram
-
Publication number: 20100047164Abstract: Chondroition sulfate proteoglycans represent excellent targets for anti-tumor immunotherapy. Antibodies which target such proteoglycans can be used alone, in combinations, armed with a cytotoxic payload or unarmed. Combinations of such antibodies can target different epitopes of the proteoglycans. Internalization of the antibodies can increase the toxicity of the payloads. Single chain variable regions are especially advantageous for such anti-tumor immunotherapy.Type: ApplicationFiled: April 6, 2009Publication date: February 25, 2010Applicants: DUKE UNIVERSITY, The United States Government as represented by the Secretary, Department of Health and Human Service, Scripps Clinic and Research FoundationInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Ralph Reisfeld
-
Publication number: 20090269343Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: ApplicationFiled: April 6, 2009Publication date: October 29, 2009Applicants: Duke University, The United States Government as represented by the Secretary, Department of Health and Human ServiceInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles N. Pegram
-
Patent number: 5211657Abstract: The present invention relates to peptides and derivatives thereof having laminin-like activity. The invention further relates to pharmaceutical compositions containing these peptides, to antibodies effective against these peptides, and to vectors containing a DNA sequence of cDNA coding for the A chain of laminin. The peptides of the invention may be used to treat diseases such as cancer.Type: GrantFiled: November 7, 1988Date of Patent: May 18, 1993Assignee: The United States Government as represented by the Secretary of the Department of Health and Human ServicesInventors: Yoshihiko Yamada, Makoto Sasaki, Hynda K. Kleinman, George R. Martin
-
Patent number: 5114589Abstract: A type-XLL cross-axis synchronous flow-through coil planet centrifuge including exclusively left-handed column coils and a method of separating macromolecules utilizing the same. The exclusive use of left-handed column coils allows retention of the stationary phase when utilizing aqueous-aqueous two-phase solvent systems. The cross-axis synchronous flow-through coil planet centrifuge has been utilized to separate proteins utilizing an aqueous-aqueous polymer phase solvent system.Type: GrantFiled: January 17, 1991Date of Patent: May 19, 1992Assignee: The United States Government as represented by the Secretary of the Department of Health and Human ServicesInventors: Yoichi Shibusawa, Yoichiro Ito